Buy Rating Affirmed for PAVmed on Growth and Valuation Prospects Amidst Product Commercialization
Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Buy Rating Affirmed for PAVmed With Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target
PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript
Analysts Offer Insights on Healthcare Companies: PAVmed (PAVM) and Simulations Plus (SLP)
Q4 2023 PAVmed Inc Earnings Call
Earnings Call Summary | PAVmed(PAVM.US) Q4 2023 Earnings Conference
The following is a summary of the PAVmed Inc. (PAVM) Q4 2023 Earnings Call Transcript:Financial Performance:PAVmed Inc. reported a 33% increase in quarterly revenue from Lucid Diagnosis primarily from
PAVmed Non-GAAP EPS of -$1.33 Beats by $0.47, Revenue of $1.05M Beats by $0.02M
PAVmed 4Q Loss/Shr $1.98 >PAVM
PAVmed 4Q Loss/Shr $1.98 >PAVM
Press Release: PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results PR Newswire NEW YORK, March 26, 2024 Lucid's quarterly revenue increased 33 percent sequentially Launched wh
PAVmed Q4 2024 Earnings Preview
Lucid Diagnostics Announces Positive Data From the First Prospective Clinical Validation Study of EsoGuard Esophageal Precancer Testing in a Screening Population
PAVmed Launches Incubator to Advance Existing Pipeline Technologies Including PortIO, EsoCure and CarpX
The incubator, PMX, and medical device firm Hatch Medical, execute joint venture agreement to complete their development and commercialization, starting with PortIO NEW YORK, March 21, 2024 /PRNewswi
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
PAVmed Inc. Distributes Lucid Stock and Adjusts Warrant Terms
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck Esophageal Cell Collection Device During Congressional Testimony
No Data